CRISPR insider plans sale of 10,400 shares

An affiliate of CRISPR Therapeutics has filed a Rule 144 notice to sell 10,400 common shares on NASDAQ.

Rhea-AI Filing Summary

CRISPR Therapeutics AG (CRSP) received a notice that James Ramon Kasinger plans to sell common shares under Rule 144. The notice covers 10,400 common shares, to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate value of $626,459.60 as of September 22, 2026, on NASDAQ.

Key Figures

Common shares to be sold: 10,400 shares Aggregate value of shares: $626,459.60 Planned sale date: September 22, 2026 +2 more

5 metrics

Common shares to be sold 10,400 shares Shares of CRISPR Therapeutics AG common stock covered by the Rule 144 notice

Aggregate value of shares $626,459.60 Aggregate value associated with the 10,400 common shares as of September 22, 2026

Planned sale date September 22, 2026 Date shown for the securities information and securities to be sold

Security type Common stock Class of CRISPR Therapeutics AG securities covered by the notice

Broker-dealer Morgan Stanley Smith Barney LLC Firm listed to execute the sale of the common shares

Key Terms

Rule 144, Securities To Be Sold, Stock Option Exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Securities To Be Sold financial

"144: Securities To Be Sold Common | 09/22/2026 | Stock Option Exercise"

Stock Option Exercise financial

"Common | 09/22/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for CRISPR Therapeutics (CRSP)?

The Form 144 reports that James Ramon Kasinger has notified regulators of an intent to sell 10,400 common shares of CRISPR Therapeutics AG under Rule 144. It is a disclosure of a potential sale by an affiliate or insider, not a transaction by the company itself.

How many CRSP shares are covered by this Rule 144 notice?

The notice covers 10,400 common shares of CRISPR Therapeutics AG. This amount appears both in the securities information and in the planned transaction section labeled “Securities To Be Sold.”

What is the approximate value of the CRSP shares in this Form 144?

The filing lists an aggregate value of $626,459.60 for the 10,400 common shares referenced. This figure reflects the value used in the Form 144 disclosure as of September 22, 2026.

When are the CRSP shares in this Form 144 intended to be sold?

The Form 144 specifies the date September 22, 2026 in both the securities information and the “Securities To Be Sold” section. This date is used as the reference for the planned sale and the valuation disclosed.

How will the CRSP shares be sold according to this Form 144?

The Form 144 indicates the common shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with the transaction described as a Stock Option Exercise settled in cash on September 22, 2026.

Who is the person selling CRSP shares under this Form 144?

The notice names James Ramon Kasinger as the person for whose account the 10,400 common shares of CRISPR Therapeutics AG are to be sold. The signature block also shows “/s/ James Ramon Kasinger.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:43 PM Accepted by SEC EDGAR 09/22/2026 - 04:42 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001708172
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CRISPR THERAPEUTICS AG
SEC File Number	001-37923
Address of Issuer	Baarerstrasse 14 Zug SWITZERLAND 6300
Phone	41 (0)41 561 32 79
Name of Person for Whose Account the Securities are To Be Sold	JAMES KASINGER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10400	626459.60	96692653	09/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/22/2026	Stock Option Exercise	Issuer			10400	09/22/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ James Ramon Kasinger
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)